IP Library Granted Patent US 7,189,746
Granted Patent B2
US 7,189,746 · App. 10/290,657 · Granted Mar 13, 2007

Methods for promoting wound healing

Assignee: GliaMed, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,189,746
App. No.
10/290,657
Granted
Mar 13, 2007
Kind
B2
Abstract

The present invention provides methods for promoting healing of a wound in a and for promoting regeneration of epithelial tissue in a subject comprising administering an effective amount of 2,2′-(1,3,4-oxadiazole-2,5-diyl)bis[1-(3,3-dimethyl-1,2-dioxopentyl)-pyrrolidine (GM-284).

Claims (27)

1. A method for promoting healing of a wound in a subject, comprising the step of administering to the subject an amount of 2,2′-(1,3,4-oxadiazole-2,5-diyl)bis[1-(3,3-dimethyl-1,2-dioxopentyl)-pyrrolidine, GM-284, effective to promote healing of the wound in the subject.

2. The method of claim 1 , wherein wound healing is promoted in the subject by promoting regeneration of epithelial tissue at the site of the wound.

3. The method of claim 2 , wherein regeneration of epithelial tissue at the site of the wound in the subject is promoted by enhancing proliferation of keratinocytes at the site of the wound.

4. The method of claim 1 , wherein wound healing is promoted in the subject by enhancing regeneration of at least one damaged neurite at the site of the wound.

5. The method of claim 4 , wherein the neurite is selected from the group consisting of an autonomic neuron neurite, a DRG neurite, an enteric neuron neurite, an interneuron neurite, a motor neuron neurite, a peripheral neuron neurite, a sensory neuron neurite, and a neurite of the spinal cord.

6. The method of claim 1 , wherein wound healing is promoted in the subject by enhancing remyelination of at least one damaged neurite at the site of the wound in the subject.

7. The method of claim 6 , wherein the neurite is selected from the group consisting of an autonomic neuron neurite, a DRG neurite, an enteric neuron neurite, an interneuron neurite, a motor neuron neurite, a peripheral neuron neurite, a sensory neuron neurite, and a neurite of the spinal cord.

8. The method of claim 1 , wherein the subject is a mammal.

9. The method of claim 8 , wherein the mammal is a human.

10. The method of claim 1 , wherein the amount of GM-284 is between about 1 mg/kg and about 10 mg/kg.

11. The method of claim 10 , wherein the amount of GM-284 is about 5 mg/kg.

12. The method of claim 1 , wherein the amount of GM-284 is between about 0.1pM and about 5 mM.

13. The method of claim 12 , wherein the amount of GM-284 is between about 5 pM and about 1.5 mM.

14. The method of claim 1 , wherein the GM-284 is administered to the subject by oral administration, parenteral administration, sublingual administration, topical administration, transdermal administration, or osmotic pump.

15. The method of claim 14 , wherein the GM-284 is administered to the subject by topical administration.

16. A method for promoting regeneration of epithelial tissue in a subject, comprising the step of administering to the subject an amount of 2,2′-(1,3,4-oxadiazole-2,5-diyl)bis[1-(3,3-dimethyl-1,2-dioxopentyl)-pyrrolidine, GM-284, effective to promote regeneration of epithelial tissue in the subject.

17. The method of claim 16 , wherein the epithelial tissue is keratinizing epithelial tissue.

18. The method of claim 16 , wherein regeneration of epithelial tissue in the subject is promoted by enhancing proliferation of keratinocytes in the subject.

19. The method of claim 16 , wherein regeneration of epithelial tissue is promoted at the site of a wound in the subject.

20. The method of claim 16 , wherein the subject is a mammal.

21. The method of claim 20 , wherein the mammal is a human.

22. The method of claim 16 , wherein the amount of GM-284 is between about 1 mg/kg and about 10 mg/kg.

23. The method of claim 22 , wherein the amount of GM-284 is about 5 mg/kg.

24. The method of claim 16 , wherein the amount of GM-284 is between about 0.1 pM and about 5 mM.

25. The method of claim 24 , wherein the amount of GM-284 is between about 5 pM and about 1.5 mM.

26. The method of claim 16 , wherein the GM-284 is administered to the subject by oral administration, parenteral administration, sublingual administration, topical administration, transdermal administration, or osmotic pump.

27. The method of claim 26 , wherein the GM-284 is administered to the subject by topical administration.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2011
From: GLIAMED, INC.
To: GLIAMED, INC.
Reel/Frame 026071/0914 →
SECURITY AGREEMENT Recorded Apr 18, 2006
From: GLIAMED, INC.
To: KERN INTER-VIVOS REVOCABLE TRUST, ANDREW E.; WOLFF, IVAN; GOLDSTEEN, DAVID; WEINSTEIN, DAVID E.; NORTHLEA PARTNERS LTD.; BARRY, MICHAEL; ZALASKY, JEFF; IVERSON, JON; GOLDSTEIN, SUSAN
Reel/Frame 017489/0630 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2003
From: WEINSTEIN, DAVID E.
To: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY
Reel/Frame 014212/0602 →
Continuity (1)
Related Publication 20040092440A1 · May 13, 2004